|
1
|
Toh JW, de Souza P, Lim SH, Singh P, Chua
W, Ng W and Spring KJ: The potential value of immunotherapy in
colorectal cancers: Review of the evidence for programmed death-1
inhibitor therapy. Clin Colorectal Cancer. 15:285–291. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dong ZY, Wu SP, Liao RQ, Huang SM and Wu
YL: Potential biomarker for checkpoint blockade immunotherapy and
treatment strategy. Tumour Biol. 37:4251–4461. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jakóbisiak M and Lasek W: Immunologia
nowotworówGołąb J, Jakóbisiak M, Lasek W and Stokłosa T: 5th
Edition. Immunologia. Wydawnictwo Naukowe PWN; Warszawa: pp.
478–484. 2007, (In Polish).
|
|
4
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weedon D, LeBoit G, Burg G and Sarasin A:
Pathology and Genetics of Tumours of the Skin. IARC Press. ISBN 92
83 224140. 2005
|
|
6
|
Thomas NE, Busam KJ, From L, Kricker A,
Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R,
Rosso S, et al: Tumor-infiltrating lymphocyte grade in primary
melanomas is independently associated with melanoma-specific
survival in the population-based genes, environment and melanoma
study. J Clin Oncol. 31:4252–4259. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Taylor RC, Patel A, Panageas KS, Busam KJ
and Brady MS: Tumor-infiltrating lymphocytes predict sentinel lymph
node positivity in patients with cutaneous melanoma. J Clin Oncol.
25:869–875. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fanoni D, Tavecchio S, Recalcati S, Balice
Y, Venegoni L, Fiorani R, Crosti C and Berti E: New monoclonal
antibodies against B-cell antigens: Possible new strategies for
diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett.
134:157–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thompson RH, Gillett MD, Cheville JC,
Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen
L, et al: Costimulatory B7-H1 in renal cell carcinoma patients:
Indicator of tumor aggressiveness and potential therapeutic target.
Proc Natl Acad Sci USA. 101:pp. 17174–17179. 2004, View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs Working Group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heppner Ingold B, Untch M, Denkert C,
Pfitzner BM, Lederer B, Schmitt W, Eidtmann H, Fasching PA, Tesch
H, Solbach C, et al: Tumor-infiltrating lymphocytes: A predictive
and prognostic biomarker in neoadjuvant-treated HER2-positive
breast cancer. Clin Cancer Res. 22:5747–5754. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al:
Prognostic and predictive value of tumor-infiltrating lymphocytes
in a phase III randomized adjuvant breast cancer trial in
node-positive breast cancer comparing the addition of docetaxel to
doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin
Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes (TILs) in
triple negative breast cancers (TNBC) from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Loi S, Michiels S, Salgado R, Sirtaine N,
Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V,
Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in
triple negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: Results from the FinHER trial. Ann
Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
NCCN Clinical Practice Guidelines in
Oncology: Colon Cancer. https://www.nccn.org.aspJanuary 20–2017
|
|
18
|
Turnbull RB Jr, Kyle K, Watson FR and
Spratt J: Cancer of the colon: The influence of the no touch
isolation technique on survival rates. Ann Surg. 166:420–427. 1967.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin Q, Wei Y, Ren L, Zhong Y, Qin C, Zheng
P, Xu P, Zhu D, Ji M and Xu J: Tumor deposit is a poor prognostic
indicator in patients who underwent simultaneous resection for
synchronous colorectal liver metastases. Onco Targets Ther.
8:233–240. 2015.PubMed/NCBI
|
|
21
|
Huijbers A, Tollenaar RA, Pelt VGW,
Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley
R, Warren BF, et al: The proportion of tumor-stroma as a strong
prognosticator for stage II and III colon cancer patients:
Validation in the VICTOR trial. Ann Oncol. 24:179–185. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morodomi T, Isomoto H, Shirouzu K,
Kakegawa K, Irie K and Morimatsu M: An index for estimating the
probability of lymph node metastasis in rectal cancers. Lymph node
metastasis and the histopathology of actively invasive regions of
cancer. Cancer. 63:539–543. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klintrup K, Mäkinen JM, Kauppila S, Väre
PO, Melkko J, Tuominen H, Tuppurainen K, Mäkelä J, Karttunen TJ and
Mäkinen MJ: Inflammation and prognosis in colorectal cancer. Eur J
Cancer. 41:2645–2654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Richards CH, Flegg KM, Roxburgh CS, Going
JJ, Mohammed Z, Horgan PG and McMillan DC: The relationships
between cellular components of the peritumoural inflammatory
response, clinicopathological characteristics and survival in
patients with primary operable colorectal cancer. Br J Cancer.
106:2010–2015. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Väyrynen JP, Sajanti SA, Klintrup K,
Mäkelä J, Herzig KH, Karttunen TJ, Tuomisto A and Mäkinen MJ:
Characteristics and significance of colorectal cancer associated
lymphoid reaction. Int J Cancer. 134:2126–2135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ueno H, Jones AM, Wilkinson KH, Jass JR
and Talbot IC: Histological categorization of fibrotic cancer
stroma in advanced rectal cancer. Gut. 53:581–586. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Frisch M, Biggar RJ, Engels EA and Goedert
JJ: AIDS-Cancer Match Registry Study Group: Association of cancer
with AIDS-related immunosuppression in adults. JAMA. 285:1736–1745.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pernot S, Terme M, Voron T, Colussi O,
Marcheteau E, Tartour E and Taieb J: Colorectal cancer and
immunity: What we know and perspectives. World J Gastroenterol.
20:3738–3750. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shankaran V, Ikeda H, Bruce AT, White JM,
Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes
prevent primary tumour development and shape tumour immunogenicity.
Nature. 410:1107–1111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jass JR, Ajioka Y, Allen JP, Chan YF,
Cohen RJ, Nixon JM, Radojkovic M, Restall AP, Stables SR and Zwi
LJ: Assessment of invasive growth pattern and lymphocytic
infiltration in colorectal cancer. Histopathology. 28:543–548.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ogino S, Nosho K, Irahara N, Meyerhardt
JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M,
Tanaka N, et al: Lymphocytic reaction to colorectal cancer is
associated with longer survival, independent of lymph node count,
microsatellite instability, and CpG island methylator phenotype.
Clin Cancer Res. 15:6412–6420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Seitz S, Schneider CK, Malotka J, Nong X,
Engel AG, Wekerle H, Hohlfeld R and Dornmair K: Reconstitution of
paired T cell receptor alpha- and beta-chains from microdissected
single cells of human inflammatory tissues. Proc Natl Acad Sci USA.
103:pp. 12057–12062. 2006, View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huh JW, Lee JH and Kim HR: Prognostic
significance of tumor-infiltrating lymphocytes for patients with
colorectal cancer. Arch Surg. 147:366–372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pagès F, Galon J and Fridman WH: The
essential role of the in situ immune reaction in human colorectal
cancer. J Leukoc Biol. 84:981–987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pagès F, Berger A, Camus M, Sanchez-Cabo
F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte
D, et al: Effector memory T cells, early metastasis, and survival
in colorectal cancer. N Engl J Med. 353:2654–2666. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Perez RO, Habr-Gama A, dos Santos RM,
Proscurshim I, Campos FG, Rawet V, Kiss D and Cecconello I:
Peritumoral inflammatory infiltrate is not a prognostic factor in
distal rectal cancer following neoadjuvant chemoradiation therapy.
J Gastrointest Surg. 11:1534–1540. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ishizuka M, Nagata H, Takagi K and Kubota
K: Influence of inflammation-based prognostic score on mortality of
patients undergoing chemotherapy for far advanced or recurrent
unresectable colorectal cancer. Ann Surg. 250:268–272. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wagner P, Koch M, Nummer D, Palm S,
Galindo L, Autenrieth D, Rahbari N, Schmitz-Winnenthal FH,
Schirrmacher V, Büchler MW, et al: Detection and functional
analysis of tumor infiltrating T-lymphocytes (TIL) in liver
metastases from colorectal cancer. Ann Surg Oncol. 15:2310–2317.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schweiger T, Berghoff AS, Glogner C,
Glueck O, Rajky O, Traxler D, Birner P, Preusser M, Klepetko W and
Hoetzenecker K: Tumor-infiltrating lymphocyte subsets and tertiary
lymphoid structures in pulmonary metastases from colorectal cancer.
Clin Exp Metastasis. 33:727–739. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fu Z, Zuo Y, Li D, Xu W, Li D, Chen H and
Zheng S: The crosstalk: Tumor-infiltrating lymphocytes rich in
regulatory T cells suppressed cancer-associated fibroblasts. Acta
Oncol. 52:1760–1770. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Barsky SH and Gopalakrishna R: Increased
invasion and spontaneous metastasis of BL6 melanoma with inhibition
of the desmoplastic response in C57 BL/6 mice. Cancer Res.
47:1663–1667. 1987.PubMed/NCBI
|
|
43
|
Prall F, Dührkop T, Weirich V, Ostwald C,
Lenz P, Nizze H and Barten M: Prognostic role of CD8+
tumor-infiltrating lymphocytes in stage III colorectal cancer with
and without microsatellite instability. Hum Pathol. 35:808–816.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Stumpf M, Hasenburg A, Riener MO, Jütting
U, Wang C, Shen Y, Orlowska-Volk M, Fisch P, Wang Z, Gitsch G, et
al: Intraepithelial CD8-positive T lymphocytes predict survival for
patients with serous stage III ovarian carcinomas: Relevance of
clonal selection of T lymphocytes. Br J Cancer. 101:1513–1521.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Workel HH, Komdeur FL, Wouters MC, Plat A,
Klip HG, Eggink FA, Wisman GB, Arts HJ, Oonk MH, Mourits MJ, et al:
CD103 defines intraepithelial CD8+ PD1+
tumour-infiltrating lymphocytes of prognostic significance in
endometrial adenocarcinoma. Eur J Cancer. 60:1–111. 2016.
View Article : Google Scholar : PubMed/NCBI
|
